The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials (Q59791503)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

title

The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

8

Giovanni Passalacqua

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

author name string

Manlio Milanese

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

Giovanni Rolla

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

Carlo Lombardi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

Caterina Bucca

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

Enrico Heffler

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

Giorgio Walter Canonica

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

publication date

6 December 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

The World Allergy Organization Journal

14 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

page(s)

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

14 April 2020

cites work

1 reference

12 December 2020

External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?

1 reference

12 December 2020

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

1 reference

12 December 2020

Pragmatic Trials — Guides to Better Patient Care?

1 reference

12 December 2020

Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness

1 reference

12 December 2020

Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations

1 reference

12 December 2020

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

12 December 2020

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

12 December 2020

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

12 December 2020

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma

1 reference

12 December 2020

Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address.

1 reference

12 December 2020

Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?

1 reference

12 December 2020

Nasal polyps in patients with asthma: prevalence, impact, and management challenges

1 reference

12 December 2020

The path to personalized medicine in asthma.

1 reference

12 December 2020

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.

1 reference

12 December 2020

Severe and Difficult-to-Treat Asthma in Adults

1 reference

12 December 2020

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma

1 reference

12 December 2020

Eosinophils and eosinophil-associated diseases: An update

1 reference

12 December 2020

10.1186/S40413-018-0210-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

14 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555618 AND SRC:MED&resulttype=core&format=json

14 April 2020

PubMed publication ID

30555618

1 reference